Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib in Japanese patients with relapsed or refractory lymphoma
NCT02598570Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of duvelisib in lymphoma, sponsored by AbbVie Inc. Primary endpoints: Treatment-emergent Adverse Events at 2 years, Maximum Observed Plasma Concentration and 2 more. Started Nov 2015; status: completed.
02
Drugs
duvelisib
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT02598570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598570.